

CT26 TTPKO cell line

Catalogue number: 157876

Sub-type: Continuous

Images:

Contributor

Inventor: Julian Downward

Institute: The Francis Crick Institute

Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: CT26 TTPKO cell line

Alternate name: TTP

Class:

Conjugate:

Description: CRISPR/Cas tristetraprolin (TTP) Knock-out KRAS mutant colon carcinoma cell line. In some immunoresistant tumours, PD-L1 expression is upregulated by RAS activation. Via the MEK pathway, the MK2 kinase phosphorylates and inhibits TTP, which negatively regulates PD-L1 expression. PD-L1 is a therapeutic target to check the immune evasion mechanism of some cancers. CRISPR edited CT26 cells.

Purpose:

Parental cell: CT26 ATCC-CRL-2638

Organism: Mouse

Tissue:

Model: Knock-Out

Gender:

Isotype:

Reactivity:

Selectivity:

Host:

Immunogen:

Immunogen UNIPROT ID:

Sequence:

Growth properties:

Production details: CRISPR/Cas TTP Knock-out KRAS mutant colon carcinoma cell line. Knock Out of functional TTP was confirmed by Western blot. Complete Zfp36 allele disruption was confirmed by

TOPO-TA cloning followed by sequencing. Mouse Zfp36 was targeted with gRNA sequence GTCATGGCTCATCGACTGGAGG, using U6gRNA-Cas9-2A-GFP

Formulation:

Recommended controls: CT26 ATCC-CRL-2638 parental cells

Bacterial resistance:

Selectable markers:

Additional notes: CRISPR edited CT26 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide...

Target details

Target: Tristetraprolin (TTP)

Target alternate names:

Target background:

Molecular weight:

IC₅₀:

Applications

Application:

Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

Handling

Format: Frozen

Concentration:

Passage number:

Growth medium: RPMI-1640 + 10% FCS. Subculture split ratio of 1:4 to 1:10 every 2-3 days.

Temperature:

Atmosphere:

Volume:

Storage medium:

Storage buffer:

Storage conditions:

Liquid Nitrogen

Shipping conditions: Dry ice

Related tools

Related tools:

References

References: Jesus et al. 2015. Virology. 481:1-12. PMID: 25765002.

CancerTools.org